TG Therapeutics Study for Relapsing Multiple Sclerosis
Research Study to Evaluate Efficacy When Transitioning to Ublituximab
The ENHANCE Study is looking for people with relapsing forms of multiple sclerosis (RMS) who are currently being treated with Disease Modifying Therapy (DMT) to take part.
This 48-week study is to determine the efficacy and safety when switching from your current DMT to ublituximab and to determine if giving it over a shorter infusion time is safe and tolerable. If transitioning from another anti-CD20 therapy you may be eligible for a modified dosing schedule to eliminate the initial 150 mg dose of ublituximab.
For more information about this study, download the study flyer.
What is the study drug?
Ublituximab is approved by the US Food and Drug Administration (FDA) with the name BRIUMVI®, for adults with relapsing forms of multiple sclerosis. In this study, ublituximab is considered investigational because the initial dose of ublituximab may be different than the initial dose currently approved by the FDA, and some doses may be administered over shorter periods of time than the time currently approved by the FDA.
If transitioning from another anti-CD20 therapy you may be eligible for a modified dosing schedule to eliminate the initial 150 mg dose of ublituximab.
Who can take part in the study?
You, or someone you care for, may be able to take part if you/they:
- Must be 18-65 years old
- Must not have been treated previously with ublituximab, alemtuzumab, cladribine, cyclophosphamide, mitoxantrone or daclizumab
- Must be neurologically stable for the past 30 days
- Must not have a history of severe or life-threatening Infusion Related Reaction on prior anti-CD20 therapy
Interested in taking part in a clinical trial?
If you are interested in taking part in one of our active clinical trials, fill out the form below and one of our team members will reach out to you with more information.